ClinicalTrials.gg
RecruitingNCT07251114Updated Nov 26, 2025

AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomized Cohort Study

An interventional study of Artificial Intelligence system in Esophageal Cancer Stage and Early Esophageal Cancer, sponsored by Fujian Provincial Hospital. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Fujian Provincial Hospital · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
109th of 394
200 · median 80
Started
2025
with 55 others
No phase
90 of 502
35 open now
Primary completion
2027-10
later than 187 of 237 live
Registered
460th of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 109th largest by planned enrollment of the 394 interventional ones that give a count, is one of 56 that started in 2025, is one of 90 with no phase, reaches primary completion later than 187 of the 237 other live ones, and was the 460th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

205 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study mainly uses an artificial intelligence system to assist in the classification of the depth of invasion of early esophageal squamous cell carcinoma under ultrasound endoscopy, providing a basis for preoperative T staging and diagnosis and treatment decisions.

Read the detailed description

For patients with early esophageal squamous cell carcinoma and precancerous lesions who met the inclusion and exclusion criteria and voluntarily participated in this project, they were randomly divided into the AI group and the conventional group by central randomization, with 100 cases in each group(anticipated). Randomization method: The personnel responsible for randomization at the center (who do not participate in the inclusion of subjects) log in to the central randomization system to obtain a randomization number, and finally form a randomization allocation table. Blinding implementation: The observation group and control group determined on the random allocation table were marked as A and B respectively, and then the operating physician implemented protocol A or B. Main indicators: Grading judgment of infiltration depth, pathological consistency

03

Conditions studied

  • Esophageal Cancer Stage
  • Early Esophageal Cancer

Keywords

  • early esophageal cancer
  • Artificial Intelligence
  • EUS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Satisfy ①⑧⑨ and one of the following conditions simultaneously: ②③④⑤⑥⑦ ① Age over 18 years old, ② Esophageal ulcer, ③ low-grade intraepithelial neoplasia, ④ high-grade intraepithelial neoplasia, ⑤ patients with esophageal squamous cell carcinoma, ⑥ white patches of esophageal mucosa, ⑦ esophageal polyps, ⑧ with endoscopic examination records and detailed pathological records, ⑨ agree to participate in the study;

Exclusion criteria

Exclusion Criteria:

  • ① Patients who have undergone esophageal cancer surgery, ② those with a history of radiotherapy and chemotherapy for esophageal cancer, ③ patients with missing data.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AI Group

    Use artificial intelligence to assist in the determination of the invasion depth of early esophageal squamous cell carcinoma under endoscopic ultrasound

    Device: Artificial Intelligence system

  • No intervention
    Control group

    Routine diagnosis

Interventions

  • DeviceArtificial Intelligence system

    Use artificial intelligence to assist in the determination of the invasion depth of early esophageal squamous cell carcinoma under endoscopic ultrasound

    Also known as: Artificial Intelligence

06

What researchers measure

Primary outcomes

  1. The accuracy of grading judgment of infiltration depth

    By comparing with the postoperative pathology, the accuracy of the preoperative T grading with the assistance of the artificial intelligence grading system was verified

    Time frame: 2 years

Secondary outcomes

  1. survival rate

    3-year survival rate

    Time frame: Three years

  2. Progression Free-Survival

    The period from the start of treatment to tumor progression or death for any reason

    Time frame: 1 year

07

Study locations

1 of 5 sites recruiting
  • Fujian provincial hospital
    Fuzhou, Fujian 350001, China
    Recruiting
    • Wei Liang, MD · Contactfjsllw@163.com · +86-18120888996
    • Yanqin Xu, MD · Contact454202013@qq.com · +86-13599382138
    • Yanqin Xu, MD · Principal investigator
    • Jiayao Zheng, MD · Sub investigator
  • Affiliated Hospital of Putian University
    Putian, Fujian 351100, China
    Not yet recruiting
    • Huifeng Wu, MD · Contact453881679@qq.com · +86-13706067949
    • Huifeng Wu, MD · Principal investigator
  • Putian First Hospital
    Putian, Fujian 351100, China
    Not yet recruiting
    • Junwei Xie, MD · Contactfjslzss@163.com · +86-15105949153
    • Junwei Xie, MD · Principal investigator
    • Linyun Xue, MD · Sub investigator
  • Putian Hospital of Traditional Chinese Medicine
    Putian, Fujian 351100, China
    Not yet recruiting
    • Fangfang Pan, MD · Contact960935120@qq.com · 86-15105938179
    • Fangfang Pan, MD · Principal investigator
    • Guixiang Yu, MD · Sub investigator
  • Xianyou County General Hospital
    Putian, Fujian 351100, China
    Not yet recruiting
    • Huijing Wu, MD · Contact736161645@qq.com · +86-15205032044
    • Huijing Wu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — It involves the protection of patent technology

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Oct 2027, 23 months later.

Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 23 months is below that.

Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 26, 2025
StartEst.
Nov 20, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07251114
Lead sponsor
Fujian Provincial Hospital
Responsible party
Wei Liang (Digestive Endoscopy Center, Fujian Provincial Hospital) — Principal investigator
First posted
Nov 26, 2025
Start date
Nov 20, 2025 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 26, 2025

Study contacts

Wei Liang, MD
Contact
fjsllw@163.com
+86 -18120888996
Yanqin Xu, MD
Contact
454202013@QQ.COM
+86-13599382136
Wei Liang, MD
principal investigator · Fujian Provincial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion